We examine current evidence that the transactive response DNA-binding protein (TDP-43) plays a pathogenic role in both amyotrophic lateral sclerosis and frontotemporal dementia. Recent findings TDP-43 was recently identified as the major pathological protein in sporadic amyotrophic lateral sclerosis and in the most common pathological subtype of frontotemporal dementia, frontotemporal lobar degeneration with ubiquitinated inclusions. In these conditions, abnormal C-terminal fragments of TDP-43 are ubiquitinated, hyperphosphorylated and accumulate as cellular inclusions in neurons and glia. Cells with inclusions show absence of the normal nuclear TDP-43 localization. Recently, missense mutations in the gene encoding TDP-43 have been identified in patients with sporadic and familial amyotrophic lateral sclerosis.
Introduction
There is growing evidence that amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are closely related conditions with overlapping clinical, genetic and neuropathological features [1] . The recent identification of the transactive response (TAR) DNAbinding protein with M r 43 kDa (TDP-43) as the major pathological protein in both ALS and the most common pathological subtype of FTD, frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) [2 ,3 ] , provides the strongest evidence to date that these conditions are part of a clinicopathological spectrum of disease. Furthermore, this discovery provides important new insights into the pathogenesis of these conditions and the potential for the development of new diagnostic tests and therapies.
Transactive response DNA-binding protein-43 is the pathological protein in amyotrophic lateral sclerosis and frontotemporal lobar degeneration with ubiquitinated inclusions One of the most characteristic neuropathological features of ALS is the presence of ubiquitin-immunoreactive (ub-ir) neuronal cytoplasmic inclusions (NCI) in the degenerating motor neurons [4] . A significant proportion of ALS patients develop cognitive deficits, often with prominent frontal lobe features [5] , and are found to have additional ub-ir NCI and neurites in the frontotemporal neocortex and hippocampus [6, 7] . Similar ub-ir, tau and a-synuclein-negative cortical pathological changes (FTLD-U) are now recognized to also be the most common pathological substrate for clinical FTD in the absence of motor features [8, 9] . Until recently, it was uncertain whether FTLD-U represented a single disease process or whether it included a number of discrete entities in which the ubiquitinated protein was different. The recognition of several identifiable subtypes of FTLD-U pathological changes, each with relatively specific clinical and molecular genetic correlations, was initially interpreted as suggesting that FTLD-U was a heterogeneous collection of diseases [10, 11] . However, this issue was finally resolved, in late 2006, when two groups identified the pathological protein in both FTLD-U and ALS as being TDP-43 [2 ,3 ] .
In those initial studies, immunoblot analysis performed on the high M r insoluble protein fraction from postmortem FTLD-U brain tissue identified disease-specific bands that were excised and analyzed by liquid chromatography-mass spectrometry [2 ,3 ]. The resulting peptides were found to correspond to amino acid sequences in the C-terminal region of TDP-43. Commercially available antibodies against TDP-43 were found to consistently label the ub-ir inclusions in patients of FTLD-U and ALS ( Fig. 1 ) but not the characteristic inclusions in a variety of other neurodegenerative conditions. An interesting observation, with possible functional implications, was the fact that neurons that contained TDP-43 inclusions showed an absence of the normal diffuse nuclear staining pattern [3 ] . In addition to the normal 43 kDa band, TPD-43 immunoblot analysis of FTLD-U and ALS tissue demonstrated diseasespecific bands at approximately 25 and 45 kDa as well as a high M r smear ( Fig. 2 [12] ). The pathological proteins were shown to represent abnormal C-terminal fragments of TDP-43 that were ubiquitinated and phosphorylated.
A number of subsequent studies have confirmed that most clinical and pathological subtypes of FTLD-U and ALS are characterized by TDP-43 immunoreactive inclusions [13 ,14 ,15,16 ,17,18] . Moreover, by virtue of its greater sensitivity and specificity, TDP-43 immunohistochemistry has proved to be a powerful new tool for investigating the neuropathology of these conditions, demonstrating changes that were not previously recognized. These include TDP-43-immunoreactive cytoplasmic inclusions in glial cells of presumed oligodendroglial lineage [2 , 16 ,17,19 ] , granular neuronal cytoplasmic 'preinclusions' [20] , dystrophic neurites in the CA1 region in patients with hippocampal sclerosis [21] and more extensive extramotor pathological changes in patients with ALS, with and without dementia [20] . Antibodies raised against phosphorylated epitopes of TDP-43 have proven to be even more sensitive and specific, as they only identify the pathological forms of the protein [22 ] , whereas the use of C-terminal and N-terminal-specific antibodies has suggested that the pathological inclusions in different population of neurons may be composed of different forms of TDP-43 [23 ] . As a result, FTLD-U and ALS are now recognized as representing a clinicopathological spectrum within a new biochemical class of neurodegenerative disease, the TDP-43 proteinopathies.
Normal function of transactive response DNAbinding protein-43 in nervous system TDP-43 is a 414 amino acid nuclear protein that is encoded by the TARDBP gene on human chromosome 1p36.2 ( Fig. 3 ). It is highly conserved and ubiquitously expressed in a variety of tissues including the brain [24] . TDP-43 contains two RNA recognition motifs (RRM1: $aa 106-175 and RRM2: $aa 191-262) and a glycinerich C-terminal region ($aa 274-413) that allow it to bind single-stranded DNA, RNA and proteins [24, 25] . It was initially cloned as a human protein capable of binding to the TAR DNA of human HIV-1, where it acts as a transcription repressor [26] . It was subsequently identified as part of a complex involved in splicing the cystic fibrosis transmembrane conductance regulator gene [24] and also the apolipoprotein A-II gene [27] . The exon skipping and splicing inhibitory activity requires the glycine-rich C-terminal domain that binds to several members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family [25, 28] . TDP-43 has also been shown to act as a scaffold for nuclear bodies through an interaction with survival motor neuron protein [29] . It may also be involved in mRNA stability, microRNA biogenesis, apoptosis and cell division [30 ] . In the brain, TDP-43 is normally localized to the nucleus of neurons and some glial cells [3 ] . Although its physiological function in the nervous system is not currently known, one recent study has suggested that it may act as a neuronal activityresponse factor involved in the regulation of neuronal plasticity [31] .
The spectrum of transactive response DNA-binding protein-43 proteinopathies
Although initial reports suggested that pathological TDP-43 is both a specific and sensitive marker of all subtypes of FTLD-U and ALS [2 ,3 ,14 ], subsequent studies have identified some important exceptions. Although the vast majority of sporadic FTLD-U patients are found to be TDP-43 positive, most large series have identified a small proportion in which the ub-ir pathological changes are negative [13 ,21] . Two recent studies have provided a detailed description of these 'atypical' patients (aFTLD-U), which represented 10-20% of all FTLD-U in the respective series [32 ,33] . In contrast to TDP-43-positive patients, all aFTLD-U patients were sporadic with very early-onset FTD, characterized by severe progressive psychobehavioral abnormalities in the absence of significant aphasia, cognitive-intellectual dysfunction or motor features. The neuropathology consisted of NCI and unique neuronal intranuclear inclusions that were only reactive for ubiquitin. On the basis of the unusual and highly consistent clinical phenotype and neuropathology, the authors suggested that aFTLD-U represents a newly recognized and specific disease entity.
In familial FTLD-U, different patterns of TDP-43 disease have been found to correlate with most of the known genetic causes, including mutations in the genes encoding progranulin and valosin-containing protein and in families with FTD and motor neuron disease linked to chromosome 9p21-13 [13 ,15,18 ]. An exception is FTD linked to chromosome 3, caused by a mutation in the gene encoding the charged multivesicular body protein gene (CHMP2B), which is characterized by ub-ir NCI in hippocampal granule cells that are not reactive for TDP-43 [13 ,34 ] .
In ALS, TDP-43-positive inclusions, in both lower motor neurons and glia, are a consistent feature of all sporadic and familial patients without SOD1 mutations [16 ,17] . However, the absence of immunohistochemical or biochemical evidence of pathological TDP-43 in humans and animal models with SOD1 mutations suggests that neurodegeneration in these cases may have a different pathogenesis [16 ,17,35 ] .
A number of recent studies have also raised questions about the specificity of TDP-43 disease by demonstrating some degree of positivity in a variety of conditions outside the usual spectrum of FTD and ALS. TDP-43 immunoreactivity is reported to be a consistent feature [42, 43] . In most of these conditions, TDP-43 pathological changes are anatomically restricted to mesial temporal structures, show only partial colocalization with the other pathological changes and are of uncertain clinical relevance [38 , [39] [40] [41] [42] [43] .
It is anticipated that our understanding of the spectrum of TDP-43 proteinopathies will continue to evolve as more patients and additional conditions are examined. Rather than diminish the importance of this protein in the pathogenesis of ALS and FTD, this new information will help clarify the relationship between different ALS and FTD subtypes and their relationship with other neurodegenerative conditions.
Mutations in TARDBP cause amyotrophic lateral sclerosis but not dementia
Rare pathogenic missense mutations and multiplications have been identified in genes encoding the major constituents of the pathological deposits in several neurodegenerative diseases [44] [45] [46] . The gene encoding TDP-43 (TARDBP) therefore represents an excellent candidate for causing or increasing the risk of developing a disease in the spectrum of TDP-43 proteinopathies. Initial sequence analyses of TARDBP in patients with sporadic FTD and ALS, as well as familial FTD, failed to identify mutations [47] . Similarly, no evidence of genetic variation in TARDBP increasing the risk for FTD or ALS was observed [47] [48] [49] . However, subsequent large population-based TARDBP mutation screenings, by us and by others, have identified 16 different missense mutations in 19 genealogically unrelated ALS patients, which were absent in healthy controls [50 ,51 ,52,53 ,54 ,55] (Fig. 3 ). Eight mutations have been found in familial ALS patients [50 ,51 ,52,53 ,54 ,55] , whereas eight others were identified in patients with sporadic ALS [51 ,53 ] . Mutations c.1077G>A (p.A315T), c.1009A>G (p.M337V) and c.1278G>A (p.A382T) were identified in two families each, and haplotype-sharing studies supported a common genetic origin for the p.A382T mutation. TARDBP mutations were not restricted to white ALS populations; mutation c.892G>A (p.G298S) was identified in a Chinese family [54 ] and c.1028A>G (p.Q343R) in a Japanese family [55] .
Depending on the study, the overall TARDBP mutation frequency in ALS has ranged from 3 to 6%, with the exception of the initial report by Sreedharan et al. [53 ] , in which a much lower TARDBP mutation frequency of 0.6% (3/526) was identified. Both population-based studies in which sporadic mutation carriers were identified described comparable TARDBP frequencies for sporadic and familial ALS [51 ,53 ] ; however, mutation analyses in a large clinical series of sporadic ALS patients of European descent did not identify mutations [56] , and other studies have identified TARDBP mutations exclusively in familial ALS [50 ,54 ,55] . Without supportive functional data, the pathogenic character of each of the TARDBP mutations identified in a single sporadic ALS patient remains uncertain. [50 ,51 ,52,53 ,54 ,55] . The mean duration of disease was 4.3 AE 3.6 years (n ¼ 18; range 1-12 years). Even within a single family, the age of onset varied significantly (by as much as 35 years) [54 ] , suggesting that additional genetic or environmental factors or both determine the disease expression of TARDBP mutations. Thirty-three per cent of mutation carriers (11/33) had bulbar-onset and 67% (22/33) had limb-onset ALS, a distribution comparable to non-TARDBP mutation carriers [57, 58] . Interestingly, despite the common co-occurrence of cognitive symptoms in ALS patients [5] , none of the TARDBP mutation carriers published to date have had a personal or family history of dementia. In agreement with this finding, TARDBP mutations have not been identified in patients with FTD, FTD-ALS or Alzheimer's disease, characterized by TDP-43 disease [51 ,52,54 ] .
Thus far, pathological examination has only been performed in two families with TARDBP mutations [54 ,55] . The neuropathological changes in patients from both families were characteristic of ALS, with motor neuron loss, gliosis and the presence of Bunina bodies. As expected, TDP-43-positive NCIs and glial cytoplasmic inclusions were observed in the ventral grey matter of the spinal cord and in various other regions of the central nervous system. In one family, the authors suggested a higher frequency of TDP-43-positive 'preinclusions' than in other patients with sporadic ALS [54 ] . Biochemical analyses of TDP-43 protein extracted from the spinal cord of the autopsied case carrying the p.Q343R mutation showed elevated levels of the abnormal molecular weight fragments of approximately 25 and 45 kDa, which were previously observed in sporadic ALS and SOD-1-negative familial ALS, suggesting that TARDBP mutations may accelerate the production of these fragments [55] . Whether these neuropathological findings are characteristic of all TARDBP mutation carriers needs further confirmation.
All but one of the reported mutations cluster in TARDBP exon 6, encoding the highly conserved C-terminal region of TDP-43 ( Fig. 3) . Four mutations involve glycine residues, in close proximity of each other, in the glycine-rich region, whereas other mutations affect conserved residues in the remaining portion of the C-terminal domain. No clustering of familial versus sporadic mutations in specific regions of the gene has been observed, and no effect of the location of the mutations on the age of onset or disease duration has been demonstrated.
Role of transactive response DNA-binding protein-43 in neurodegeneration
Little is currently known about the pathogenic role of TARDBP mutations or TDP-43 disease in neurodegeneration. Analogous to other neurodegenerative diseases characterized by the accumulation of misfolded protein, the critical step will be to determine whether disease results from a loss of function, a toxic gain of function or both.
The abnormal localization of TDP-43 from the nucleus to the cytoplasm in affected neurons in FTD and ALS, irrespective of the presence of a genetic mutation, suggests a pathogenic mechanism associated with the loss of normal nuclear TDP-43 function in regulating transcription, splicing and mRNA stability [30 ,59] . In support of this hypothesis, loss of TDP-43 in human cells has been shown to induce morphological nuclear defects and increased apoptosis [60 ] . Alternatively, sequestration of TDP-43 in cellular inclusions may induce a toxic gain of function, independent of the basic biological role of TDP-43. A study in which TDP-43 was overexpressed in yeast suggested that only aggregating forms of TDP-43 were toxic, although the toxicity depended on an intact RNA recognition motif [61 ] . Factors that affect the normal intracellular trafficking of TDP-43, between the cytoplasm and nucleus, may predispose to both the formation of abnormal aggregates (inclusions) and the loss of nuclear localization [62 ].
The identification of TARDBP mutations in ALS has provided important clues to the possible pathogenic mechanisms involved in TDP-43 proteinopathies. The clustering of mutations in exon 6, which encodes the highly conserved C-terminal domain, suggests that TARDBP mutations may interfere with the normal protein-protein interactions of TDP-43, affect its transport through the nuclear pore or influence its exon skipping or transcriptional repression activity [51 ,53 ] . Numerous potential phosphorylation sites have been predicted to occur in the C-terminal region of TDP-43
The role of TDP-43 in ALS and FTD Mackenzie and Rademakers 697 and some mutations, especially the six substitutions to serine and threonine residues, may increase phosphorylation and aggregation. A single mutation c.640A>T (p.D169G) was identified in TARDBP exon 4 encoding RRM1 [51 ] . This mutation may abrogate the RNA binding to this region; however, because it lies outside exon 6 and lacks evidence of segregation with disease, it may also represent a rare benign sequence variant. Finally, a study of mutant TDP-43 in cell culture and in vivo revealed increased generation of detergentinsoluble TDP-43 fragments that could aggregate and cause a toxic gain of function [51 ,53 ] . Given the multifaceted role of TDP-43, multiple disease mechanisms may well be involved.
Conclusion
The identification of pathological TDP-43 in FTLD-U and ALS confirms that these conditions are part of a disease spectrum with a common underlying biochemical mechanism. This insight has helped in clarifying the relationship among various genetic, clinical and pathological subtypes of FTD and ALS and has suggested possible mechanistic links with other neurodegenerative disorders. A better understanding of the role of TDP-43 in neurodegeneration will be crucial to the development of targeted therapeutic strategies for these conditions. Central to this process will be the use of experimental animals and cell systems, expressing pathogenic mutations in TARDBP or other genes that cause FTLD-U. The recent identification of elevated plasma levels of TDP-43 in some patients with neurodegenerative disease [63 ] supports the possible use of TDP-43 as an in-vivo biomarker to aid in diagnosing disease and monitoring the effects of therapy. In summary, the discovery that TDP-43 plays a central role in the pathogenesis of FTD and ALS has been a major advance toward the effective management of these devastating neurodegenerative conditions.
